Case report: complete pathologic response to neoadjuvant ensartinib in locally advanced, ALK-positive lung squamous cell carcinoma
-
By
-
Yingyu Yang
-
Junkai Zhang
-
Zhirun Xie
-
Sirui Zhang
-
May 25, 2026
-
Clinical Scorecard: Case Study: Complete Pathological Response to Neoadjuvant Ensartinib in Stage IIIB ALK-Positive Lung Squamous Cell Carcinoma
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | Patients with locally advanced, ALK-positive lung squamous cell carcinoma (specificity needed). |
| Care Setting | |
Key Highlights
Guideline-Based Recommendations
Diagnosis
Management
- Neoadjuvant treatment with ensartinib followed by surgical resection (ensure direct support).
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Ensartinib administered at 225mg once daily, leading to significant tumor shrinkage (ensure direct support).
Clinical Best Practices
Related Resources & Content
